Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc NRIFF


Primary Symbol: MRVFF

Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Bullboard Posts
Comment by TurtleNamedSamon Aug 06, 2015 10:45pm
122 Views
Post# 23996724

RE:More Detailed Q2 Review/ Product Margins

RE:More Detailed Q2 Review/ Product MarginsRock07 wrote:

The patient sample size for WF10 is just 1/2 of intended levels.
This means 50 % fewer patients to monitor and 50 % less patients needing Chamber testing following the pollen season.


It also means that the statistics will be greater than 50% worse - half the number of data points means that the standard deviation will be more than twice as large as expected when the trial was devised. That is the nature of statistics.
 
Bullboard Posts